2
Feb
2025
The Future of AI and Health, Part III: Improving Health By Enhancing Agency
Part II of this series is here “Agency,” Harvard’s Zak Kohane and I agree, is the word of 2025. Kohane’s reasoning: “Patients understand how to increase their agency in their disease journey with often correct and thoughtful instant second opinions from AI.” This perspective aligns with the opportunities described by A16z VCs Vijay Pande and Marc Andreessen, as... Read More
2
Feb
2025
The Future of AI and Health, Part II: Andreessen and Colleagues Weigh In
Part I of this series is here. Over its 15 years of existence, the Andreessen Horowitz (“A16z”) venture capital firm has evolved from a media-savvy disruptive upstart to an exceedingly well-heeled incumbent and powerful force in Silicon Valley and the country. In April 2024, the firm announced a gargantuan $7.2B (with a “B”) fund. For a typical VC firm with... Read More
2
Feb
2025
The Future of AI and Health, Part I: Forecasts Reveals Little Consensus
The likely impact of AI on health and medicine is … highly dependent on who you ask. Consider the spectacularly wide range of opinions offered in just the last several weeks. A $500 billion AI project, dubbed “Stargate,” was announced with great fanfare on January 21 in the Roosevelt room of the White House by President Trump. He was flanked... Read More